• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
VRCA

VRCA

Verrica Pharmaceuticals Inc.

NASDAQHealthcareBiotechnologyUS

USD5.87

+0.08 (+1.38%)

Rating:C-

Company Profile

CEO

Jayson Rieger

IPO Date

2018-06-15

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

Country

US

Market Metrics

Open

$5.83

Prev. Close

$5.79

Day Low

$5.62

Day High

$5.96

52W Low

$3.28

52W High

$9.82

Market Cap

$0.06B

Volume

0.02M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

22.9%

Avg Negative

8.4%

Avg Neutral

68.4%

News Feed

Verrica Pharmaceuticals Announces Appointment of Terry Kohler as Chief Financial Officer

GlobeNewsWire·7/9/2021·↑ positive

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Verrica Pharmaceuticals Inc. - VRCA

PRNewsWire·6/3/2021·↓ negative

Verrica's (VRCA) Skin Disease Candidate Approval Gets Delayed

Zacks Investment Research
·5/31/2021
·↓ negative

Verrica Pharmaceuticals Announces Extension of FDA Review Period of its NDA for VP-102 for the Treatment of Molluscum Contagiosum

GlobeNewsWire·5/28/2021·↑ positive

ScPharmaceuticals: The Third Time's A Charm

Seeking Alpha·5/12/2021·↑ positive

Verrica Pharmaceuticals Announces Participation in the 2021 RBC Capital Markets Global Healthcare Conference

GlobeNewsWire·5/12/2021·↑ positive

Verrica Pharmaceuticals Reports First Quarter 2021 Financial Results

GlobeNewsWire·5/7/2021·↑ positive

Verrica Announces Election of Gary Goldenberg, MD, Verrica's Chief Medical Officer, to Membership in the American Dermatological Association

GlobeNewsWire·3/29/2021·↑ positive

Verrica Announces Pricing of Public Offering of Common Stock

GlobeNewsWire·3/22/2021·↑ positive

Verrica Pharmaceuticals Announces Participation in the H.C. Wainwright Annual Global Life Sciences Conference

GlobeNewsWire·3/3/2021·↑ positive